JP5990542B2 - 全身性エリテマトーデスのリスクスコアを算出する方法 - Google Patents

全身性エリテマトーデスのリスクスコアを算出する方法 Download PDF

Info

Publication number
JP5990542B2
JP5990542B2 JP2013553610A JP2013553610A JP5990542B2 JP 5990542 B2 JP5990542 B2 JP 5990542B2 JP 2013553610 A JP2013553610 A JP 2013553610A JP 2013553610 A JP2013553610 A JP 2013553610A JP 5990542 B2 JP5990542 B2 JP 5990542B2
Authority
JP
Japan
Prior art keywords
level
sle
marker
patients
ec4d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013553610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505264A5 (enExample
JP2014505264A (ja
Inventor
デルヴュー、ティエリー
ハリス、コール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exagen Inc
Original Assignee
Exagen Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exagen Diagnostics Inc filed Critical Exagen Diagnostics Inc
Publication of JP2014505264A publication Critical patent/JP2014505264A/ja
Publication of JP2014505264A5 publication Critical patent/JP2014505264A5/ja
Application granted granted Critical
Publication of JP5990542B2 publication Critical patent/JP5990542B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013553610A 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法 Expired - Fee Related JP5990542B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161441785P 2011-02-11 2011-02-11
US61/441,785 2011-02-11
US201161442454P 2011-02-14 2011-02-14
US61/442,454 2011-02-14
US201161472424P 2011-04-06 2011-04-06
US61/472,424 2011-04-06
PCT/US2012/024729 WO2012109592A1 (en) 2011-02-11 2012-02-10 Methods for diagnosing systemic lupus erythematosus

Publications (3)

Publication Number Publication Date
JP2014505264A JP2014505264A (ja) 2014-02-27
JP2014505264A5 JP2014505264A5 (enExample) 2015-04-02
JP5990542B2 true JP5990542B2 (ja) 2016-09-14

Family

ID=45774332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553610A Expired - Fee Related JP5990542B2 (ja) 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法

Country Status (4)

Country Link
US (6) US10132813B2 (enExample)
EP (1) EP2673644B1 (enExample)
JP (1) JP5990542B2 (enExample)
WO (1) WO2012109592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
US9863946B2 (en) 2013-02-08 2018-01-09 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
JP6400604B2 (ja) 2013-02-08 2018-10-03 アレゲーニー・シンガー リサーチ インスティチュート プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
CN105229470B (zh) * 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
US20170074876A1 (en) * 2014-03-13 2017-03-16 INSERM (Institut National de la Sante et da la Recherche Medicale) Diagnosis Method for Lupus
BR112017002575B1 (pt) * 2014-08-08 2023-11-07 Allegheny Singer Research Institute Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo
IL256399B (en) 2015-06-19 2022-09-01 Sera Prognostics Inc Biomarker pairs for predicting preterm birth
JP6674543B2 (ja) * 2015-07-31 2020-04-01 アレゲーニー・シンガー リサーチ インスティチュート 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
KR102608933B1 (ko) * 2021-10-20 2023-12-01 재단법인 아산사회복지재단 전신 홍반성 루푸스 환자의 루푸스 신염 진단용 바이오마커 조성물 및 이를 이용한 루푸스 신염 진단에 필요한 정보를 제공하는 방법
CN119889651B (zh) * 2024-12-24 2025-11-18 北京医院 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256708B2 (en) 1999-06-23 2007-08-14 Visicu, Inc. Telecommunications network for remote patient monitoring
DE60237529D1 (de) * 2001-09-10 2010-10-14 Univ Pittsburgh Diagnose und aufzeichnung von systemischem lupus erythematosus und von skleroderm
JP4550051B2 (ja) 2003-04-16 2010-09-22 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 全身性エリテマトーデスの同定およびモニタリング
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
DK1756571T3 (da) 2004-04-09 2010-12-13 Univ Pittsburgh Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
AU2005242719B2 (en) * 2004-05-11 2011-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20070148704A1 (en) * 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
EP2008213A1 (en) * 2006-04-07 2008-12-31 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Systems and methods for predicting an individual's risk of developing rheumatoid arthritus
CA2738952A1 (en) 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
WO2011047337A2 (en) * 2009-10-16 2011-04-21 Exagen Diagnostics, Inc. Cell-based complement activation product algorithm for diagnosing systemic lupus erythematosus
EP2336769A1 (en) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
ES2425540T3 (es) 2010-02-22 2013-10-16 Medipan Gmbh Procedimiento y dispositivo para la detección simultánea de anticuerpos unidos a sustratos sintéticos y celulares y/o tisulares
EP2673644B1 (en) 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2013134431A1 (en) 2012-03-06 2013-09-12 Life Technologies Corporation Biomarkers for systemic lupus erythematosus
CN105229470B (zh) 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法

Also Published As

Publication number Publication date
EP2673644B1 (en) 2016-02-10
US12372535B2 (en) 2025-07-29
US20240288441A1 (en) 2024-08-29
US11761965B2 (en) 2023-09-19
EP2673644A1 (en) 2013-12-18
US20220276259A1 (en) 2022-09-01
US11885812B2 (en) 2024-01-30
US20240003902A1 (en) 2024-01-04
US11360099B2 (en) 2022-06-14
US20230194548A1 (en) 2023-06-22
WO2012109592A1 (en) 2012-08-16
US10132813B2 (en) 2018-11-20
JP2014505264A (ja) 2014-02-27
US20190025326A1 (en) 2019-01-24
US20130309698A1 (en) 2013-11-21
HK1192316A1 (zh) 2014-08-15

Similar Documents

Publication Publication Date Title
JP5990542B2 (ja) 全身性エリテマトーデスのリスクスコアを算出する方法
US12449427B2 (en) Methods for treating and diagnosing systemic lupus erythematosus
Orme et al. A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies
US20100233752A1 (en) Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
CN107430118A (zh) 对自身免疫状况的分类与管理的方法与仪器
Brousse et al. Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis
Usui et al. Serum uromodulin is a novel renal function marker in the Japanese population
US20110177531A1 (en) Cell-Based Complement Activation Product Algorithm for Diagnosing Systemic Lupus Erythematosus
Midan et al. Clinical assessment of neutrophil gelatinase-associated lipocalin as a potential diagnostic marker for neonatal sepsis: a prospective cohort study
de Freitas et al. Evaluation of HLA-DR expression in monocytes and CD64 in neutrophils as A predictor of SEPSIS/sirs in the infectious-inflammatory process
Little et al. Evaluation of solid-phase panreactivity with negative direct antiglobulin testing
Iaremenko et al. Clinical and laboratory pattern of patients with systemic lupus erythematosus seropositive for rheumatoid factor
CN117741143B (zh) Siglec-9蛋白及其特异性抗体在制备神经梅毒或神经损伤诊断产品中的应用
Chi et al. Role of Anti-Vinculin Quantitative ELISA Test in Diagnosing Irritable Bowel Syndrome and Inflammatory Bowel Disease
Mahir et al. Performance evaluation of immunoblot for the detection of anti-DNA antibodies compared to indirect immunofluorescence on Crithidia luciliae
HK1192316B (en) Methods for diagnosing systemic lupus erythematosus
Öner et al. Reasons For Requesting the Test in Antinuclear Antibody-Positive Patients and Final Diagnosis of Patients
Pisetsky The Impact of Antinuclear Antibody Testing on the Naming and Misnaming of Disease
Chun et al. B-051 Clinical Validation of Vectra® DA: A Multi-Biomarker Based Test for the Objective Measurement of Disease Activity in Patients with Rheumatoid Arthritis
CN120539404A (zh) 一种辅助诊断系统性红斑狼疮的生物标志物及其应用
Putheti et al. T Cell Positive B Cell Negative Flow Cytometry Crossmatch (FCXM): Frequency, HLA-Locus Specificity, and Mechanisms Among 3073 Clinical FCXM Tests
Kumar et al. INNOSC Theranostics and Pharmacological Sciences

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160815

R150 Certificate of patent or registration of utility model

Ref document number: 5990542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees